Quiver Bioscience
Quiver Holdings Inc.
Quiver Bioscience was built to create transformational medicines for patients living with disorders of the brain. Utilizing human disease models, novel AI, and best-in-world platform, we stand as the premier partner in the journey from target discovery to the clinic.
quiverbioscience.com · Cambridge, MA
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$3.0M of Indefinite
Filed2026-10-21
Days since filing23
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2026-10-08
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Graham T DempseyExecutive Officer
- David LiederbachExecutive Officer
- David MarguliesExecutive Officer · Director
- Paul RomaExecutive Officer · Director
- Jonathan FlemingDirector
- Janet FouttyDirector
- Paul BlackDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$3.0M sold1.2 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-11-022
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- AI Research Scientist, Biological Foundation ModelsNOV 2Cambridge, MA · Biology · Full-Time · open 11 days
- Vice President, Business DevelopmentNOV 2Cambridge, MA · Leadership · Full-Time · open 11 days
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.